Contact us

Hangzhou Huadi Group Co., Ltd.

Address: 7th Floor, A2-2, Xixi First Block, No. 588, Wenyi West Road, Xihu District, Hangzhou, Zhejiang, China

Zip code: 310012

Office: +86-(0)571-58126395

Domestic sales: +86-(0)571-82707230


International trade: +86-(0)571-87207315

Fax: +86-(0)571-85126395


Company Profile


Hangzhou Huadi Group Co., Ltd. (hereinafter referred to as Huadi  Group) is a national high-tech enterprise. It was established in February 2011 with a registered capital of 100 million yuan. It is headquartered in Xihu District, Hangzhou, and is specialized in research and development in the field of biomedicine. The company is rich in production management, operation and management experience. It is a group company that invests in diversified industries such as pharmaceuticals, food, health products, cosmetics and bio-agricultural products.

Huadi  Group has four subsidiaries: Zhejiang Huadi Pharmaceutical Group Co., Ltd., Zhejiang Huajun Pharmaceutical Co., Ltd., Hangzhou Huajin Pharmaceutical Co., Ltd., Zhejiang Mingxi Biotechnology Co., Ltd., including 2 national high-tech companies. The technology enterprise has 2 post-doctoral workstations, several national new drug certificates and more than 10 national invention patents. It has won many Zhejiang Science and Technology Awards and Hangzhou Science and Technology Progress Award. It has also been awarded the honorary title of “AAA Credit Enterprise”, “Top 100 Most Developed Science and Technology Enterprises” and “Most Social Responsibility Enterprise in 2017” in Zhejiang Province.


Huadi Group is the vice president unit of China Biochemical Pharmaceutical Industry Association and the vice president unit of Zhejiang Health Industry Research Association. Zhejiang Huadi Pharmaceutical Group, a holding subsidiary, is the drafting unit of the GMP appendix of biochemical drugs for the national pharmaceutical production quality management standard. The Group has a provincial R&D center and has long employed domestic and foreign experts and scholars as technical consultants and has strong scientific and technological innovation strength. In particular, he has more than 20 years of experience in R&D and industrial transformation in biochemical extraction products, multi-component biochemical drugs, and synthetic peptide products. Among them, the research and development of biochemical extraction products and multi-component biochemical drugs have advanced international research level and The industrialization transformation capability is in a leading position in China.

Huadi Group's main products are: hepatocyte growth factor enteric-coated capsules, transfer factor capsules, thymopentin, oxytocin, and various biochemical extractive actives. Among them, the main product promotes hepatocyte growth factor enteric-coated capsules as the national four new drugs, the exclusive products of the country, and the patented products. It is a biologically active small molecule polypeptide obtained by biotechnology of fresh suckling pig liver-promoting hepatocyte growth factor. This ingredient stimulates DNA synthesis in hepatocytes and promotes hepatocyte regeneration and repair. The product is a biomedical product supported by the State's key high-tech fields. It has won the third prize of Zhejiang Science and Technology, the second prize of Hangzhou Science and Technology Progress Award, the national key new product certificate, and obtained three related invention patents. Since 2010, it has entered the medical insurance and agricultural insurance catalogues in more than ten provinces across the country.

The subsidiaries of Huadi Group have many modern production lines, producing nearly 100 kinds of finished drugs, APIs and pharmaceutical intermediates. The products are distributed in all provinces, municipalities and autonomous regions in China, and are exported to more than 20 countries and regions. The company has established a stable sales network nationwide, and established sales channels in more than 20 countries including the United States, Germany, India, South Korea and Russia, laying a foundation for the sales of the company's products and the marketing of new products.

Today's Huadi Group is actively pursuing diversified development channels, investing in and guiding the innovation and development of its subsidiaries, and striving to become a new force in the field of biomedicine with the full enthusiasm and in accordance with the requirements of the country to vigorously develop high-tech products in the field of biomedicine. The industry's vanguards have fully realized “industrial upgrading, capital upgrading, and talent upgrading”, and vigorously developed three new formats of medical health, biological nutrition and bio-health.

Share to the community  
Feedback Further communication
Click to send
Copyright © 2019 - 2022
Hangzhou Huabang Group Co., Ltd.